Evidence map›Paper›PMID 39317013›Full record

ArticleThrombosis research2024

Regulation of macrophage fibrinolysis during venous thrombus resolution.

Tierra A Johnson, Subhradip Mukhopadhyay, Marguerite S Buzza, Jacob A Brooks, Rajabrata Sarkar, Toni M Antalis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tierra A JohnsonCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Subhradip MukhopadhyayCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Marguerite S BuzzaCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jacob A BrooksCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Rajabrata SarkarCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Toni M AntalisCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; Research & Development Service, VA Maryland Health Care System, Baltimore, MD, 21201, USA. Electronic address: tantalis@som.umaryland.edu.

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Vu H. Duong · 2008 to 2026
$51.0M
EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Vascular Biology Training ProgramT32HL007698 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Rosemary A Kozar, Dudley K. Strickland · 1991 to 2026
$8.7M
UMB Postbaccalaureate Research Education ProgramR25GM113262 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M, CAREY, GREGORY B · 2016 to 2025
$3.2M
The effect of Myristolated alanine-rich C Kinase Substrate (MARCKS) on kinase interacting with stathmin (KIS) in differential proliferation of vascular smooth muscle and endothelial cellsR01HL134938 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SARKAR, RAJABRATA · 2017 to 2021
$1.9M
Vascular Remodeling by Membrane Serine ProteasesR01HL084387 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M · 2007 to 2010
$1.5M
Proteolytic Pathways in Venous Thrombus ResolutionI01BX001921 · VA · BALTIMORE VA MEDICAL CENTER · PI ANTALIS, TONI M · 2013 to 2025
–
BLRD VA I01 BX001921NCI NIH HHS P30 CA134274NHLBI NIH HHS R01 HL084387NHLBI NIH HHS R01 HL134938NHLBI NIH HHS T32 HL007698NIGMS NIH HHS R25 GM055036NIGMS NIH HHS R25 GM113262
6 · The paper itself

Abstract

backgroundVenous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is a serious cardiovascular disease with significant mortality and morbidity. Clinically, patients with faster resolution of a venous thrombi have improved prognosis. Urokinase-plasminogen activator (uPA), produced by macrophages, is a key mediator of fibrinolysis required for resolving venous thrombi and restoring vascular integrity. The major macrophage protein, plasminogen activator inhibitor type-2 (PAI-2), was originally identified as an inhibitor of uPA and is implicated in the modulation of pathways affecting fibrinolytic uPA activity, however its direct role in blocking uPA-mediated clot lysis is not known.

objectiveTo determine the contribution of macrophage PAI-2 in inhibiting uPA-mediated fibrinolysis during resolution of DVT.

methodsUsing a murine model of venous thrombosis and resolution, we determined histological changes and molecular features of fibrin degradation in venous thrombi from WT mice and mice genetically deficient in PAI-2 and PAI-1, and determined the fibrinolytic activities of macrophages from these genotypes ex vivo.

resultsAcceleration of venous thrombus resolution by PAI-2

conclusionPAI-2 has an alternate anti-fibrinolytic activity that is macrophage uPA independent, where PAI-1 is the dominant uPA inhibitor during DVT resolution.

Indexed as

FibrinolysisMacrophagesPlasminogen Activator Inhibitor 2Venous ThrombosisAnimalsHumansMaleMiceMice, Inbred C57BLMice, KnockoutPlasminogen Activator Inhibitor 1Urokinase-Type Plasminogen ActivatorPlasminogen Activator Inhibitor 1Plasminogen Activator Inhibitor 2Urokinase-Type Plasminogen ActivatorFibrinFibrinolysisMacrophagePAI-1PAI-2Plasminogen activator inhibitorVenous thrombosis

Identifiers

PMID39317013
PMCPMC11486561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.